Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTKLQTJ)

• DTT Name: Angiopoietin-2 (ANGPT2) DTT Info
• Gene Name: ANGPT2

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[1]

12 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[2]
Trebananib	DMOG2X1	Ovarian cancer	2C73	Phase 3	[3]
REGN910-3	DMTBRPO	Neovascular age-related macular degeneration	9B78.3Z	Phase 2	[5]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[6]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[7]
CVX-060	DM03LWZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
BI 836880	DMRI6YT	Neoplasm	2A00-2F9Z	Phase 1	[9]
CVX-241	DMV74JC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
MEDI3617	DM0H5JD	Ovarian cancer	2C73	Phase 1	[11]
Nesvacumab	DM59ZDN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
REGN-910	DMHR7D4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
Zifibancimig	DMIJ2MZ	Neovascular age-related macular degeneration	9B78.3Z	Phase 1	[14]

1 Drugs in Phase 2 Trial Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY3127804	DMAC457	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[4]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABTAA	DM79DSN	Sepsis	1G40-1G41	Investigative	[15]

References

• [1] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
• [6] Company report (Roche pipeline: July 27, 2017)
• [7] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [8] Clinical pipeline report, company report or official report of CovX (2011).
• [9] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [10] Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
• [11] Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res. 2018 Jun 15;24(12):2749-2757.
• [12] Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869.
• [13] Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.
• [14] Clinical pipeline report, company report or official report of Roche
• [15] Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55.